Impact of different fludarabine doses in the fludarabine-based conditioning regimen for unrelated bone marrow transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for patients with various hematological disorders1. Reduced-intensity conditioning (RIC) and myeloablative reduced-toxicity conditioning (RTC) regimens have been developed to reduce early non-relapse mortality (NRM) and complications associated with myeloablative conditioning (MAC) regimens. These regimens allow for the extension of HSCT to older and unsuitable patients who are unable to tolerate MAC regimens2-4.

Source: Biology of Blood and Marrow Transplantation - February 17, 2024 Category: Hematology Authors: Kodai Kuriyama, Shigeo Fuji, Ayumu Ito, Noriko Doki, Yuta Katayama, Hiroyuki Ohigashi, Tetsuya Nishida, Kentaro Serizawa, Tetsuya Eto, Naoyuki Uchida, Yoshinobu Kanda, Masatsugu Tanaka, Ken-ichi Matsuoka, Hideyuki Nakazawa, Junya Kanda, Takahiro Fukuda, Y Source Type: research